阿托格潘（库利普塔）

Canadian Journal of Health Technologies Pub Date : 2023-08-30 DOI:10.51731/cjht.2023.727

None CADTH

{"title":"阿托格潘（库利普塔）","authors":"None CADTH","doi":"10.51731/cjht.2023.727","DOIUrl":null,"url":null,"abstract":" CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses atogepant (Qulipta), 10 mg, 30 mg, and 60 mg, oral tablets. Indication: The prevention of episodic migraine (< 15 migraine days per month) in adults.","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"47 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Atogepant (Qulipta)\",\"authors\":\"None CADTH\",\"doi\":\"10.51731/cjht.2023.727\",\"DOIUrl\":null,\"url\":null,\"abstract\":\" CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses atogepant (Qulipta), 10 mg, 30 mg, and 60 mg, oral tablets. Indication: The prevention of episodic migraine (< 15 migraine days per month) in adults.\",\"PeriodicalId\":9437,\"journal\":{\"name\":\"Canadian Journal of Health Technologies\",\"volume\":\"47 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Health Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.51731/cjht.2023.727\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51731/cjht.2023.727","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

& # x0D;CADTH报销审查是对药物或药物类别的临床有效性和成本效益以及患者和临床医生观点的综合评估。评估结果提供了非约束性建议，这些建议有助于指导加拿大联邦、省和地区政府(魁北克省除外)的报销决定。本综述评估了10 mg、30 mg和60 mg的联合剂(Qulipta)口服片剂。适应症:预防发作性偏头痛(<每个月15天偏头痛)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Atogepant (Qulipta)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses atogepant (Qulipta), 10 mg, 30 mg, and 60 mg, oral tablets. Indication: The prevention of episodic migraine (< 15 migraine days per month) in adults.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Canadian Journal of Health Technologies

自引率

0.00%

发文量

期刊最新文献

Relugolix (Orgovyx) Nabilone for Chronic Non-Cancer Pain Newborn Screening for Congenital Cytomegalovirus in Canada 2023 Abstracts of the Canadian Association for Population Therapeutics The Development of a Model Validation Tool to Assist in the Conduct of Economic Evaluations